

Nabih MASLAH

Born: 10/23/1987

Nationality: French

ORCID: 0000-0002-5553-462X - <https://orcid.org/0000-0002-5553-462X>

Scholar: <https://scholar.google.com/citations?user=jzzU6IAAAAJ&hl=en>

ADDRESS

INSERM UMR-1342 – Hôpital Saint-Louis, Institut de Recherche Saint-Louis (IRSL)

1 av. Claude Vellefaux, 75010 Paris, France

Tel: +33157279012

E-mail: nabih.maslah@aphp.fr

POSITION

2024–Present. Associate Professor – Hospital Practitioner (MCU-PH), Cell Biology, Saint-Louis Hospital, Paris, France.

Member of INSERM UMR-1342, Institut de Recherche Saint-Louis (IRSL).

RESEARCH TOPICS

Myeloproliferative Neoplasms (MPN): clonal evolution, treatment-driven clonal selection, and mechanisms of therapy response/resistance with emphasis on IFN- α biology, senescence, and single-cell multi-omic approaches.

PASSED POSITIONS

2023–2025. Postdoctoral Fellow, Single Cell Analytics and Innovation Lab (SAIL), Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA.

2020–2024. Assistant Professor, Saint-Louis Hospital, Paris, France (Prof. Stéphane Giraudier).

2017–2020. PhD Candidate, Université Paris Cité, Paris, France (Prof. Jean-Jacques Kiladjian).

2015–2017. Assistant Professor, Saint-Louis Hospital, Paris, France (Prof. Christine Chomienne).

2014–2015. M.Sc. Research Fellow, Necker Hospital, Paris, France (Prof. Elizabeth Macintyre).

2010–2014. Medical Resident, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris, France.

DIPLOMAS

2020. PhD, Université Paris Cité (MPN: senescence and therapeutic targeting).

2015. Master of Science (M.Sc.), Necker Hospital, Paris (T-cell Acute Lymphoblastic Leukemias).

2014. PharmD - Medical Biology Specialty, Residency, AP-HP, Paris (Basis of hematological malignancies).

2010. PharmD, Université Paris Descartes (Cell Biology and Drug Sciences).

HONORS AND AWARDS

2024. François Wallace Monahan Fellowship, Single Cell Analytics and Innovation Lab, MSKCC.

2022. American Society of Hematology Abstract Achievement Award.

2020. PhD Thesis Award, French Association of Cell Biology (ANEBC).

2018. Award from the European School of Hematology (ESH).

2017–2019. INSERM Fellowship: “Poste d’accueil INSERM”.

2014–2015. Research Fellowship, Paris Public Hospitals: “Année Médaille”.

EXPERTISES

Reviewer in international journals: Blood, Leukemia, Haematologica

STUDENT SUPERVISION (2016–2025)

M1 Students: 10

M2 Students: 7 and 2 in co-direction

PhD Students: 2 in co-direction: Celine AOUN (HOB 561) and Panhong GOU (HOB 561)

TEACHING

Coordinator, Master 2 BMCFH – Hematopoiesis, Faculty of Life Sciences, Université Paris Cité.

Coordinator, Master 1 – Introduction to Hematology, Faculty of Life Sciences, Université Paris Cité.

Postgraduate Medical Biology Residency (DES), Hematology — advanced teaching on MPN

FUNDINGS AS PRINCIPAL INVESTIGATOR / SCIENTIFIC COORDINATOR

2025–2027. French Leukemia Institute (IHU), €80,000, Principal Investigator.

2023–2024. Fondation ARC, €30,000, Principal Investigator.

2023–2024. French League Against Cancer, €25,000, Principal Investigator.

2022–2024. French National Cancer Institute (INCa), €249,000, Scientific Coordinator (Work Package).

2024–2025. François Wallace Monahan Fellowship, MSKCC (award).

BIBLIOMETRICS

PubMed Publications (since 2017): 30

Web of Science™ H-Index: 14

Times Cited: 896

SIGAPS: 509

FIVE MAIN PUBLICATIONS

1. JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms. **Maslah N**, Kaci N, Roux B, Alexe G, Marie R, Pasquer H, Verger E, De Oliveira RD, Culeux C, Mlayah B, Gauthier N, Gonzales F, Zhao LP, Ganesan S, Gou P, Ling F, Soret-Dulphy J, Parquet N, Vainchenker W, Raffoux E, Padua RA, Giraudier S, Marty C, Plo I, Lobry C, Stegmaier K, Puissant A, Kiladjian JJ, Cassinat B, Benajiba L. *Nat Commun.* 2025 Jul 8;16(1):6270. doi: 10.1038/s41467-025-60884-1. PMID: 40623967
2. Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. **Maslah N**, Benajiba L, Giraudier S, Kiladjian JJ, Cassinat B. *Leukemia.* 2023 May;37(5):957-963. doi: 10.1038/s41375-023-01886-0. Epub 2023 Mar 31. PMID: 37002477
3. Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. **Maslah N**, Verger E, Giraudier S, Chea M, Hoffman R, Mascarenhas J, Cassinat B, Kiladjian JJ. *Blood Adv.* 2022 May 10;6(9):2813-2823. doi: 10.1182/bloodadvances.2021005867. PMID: 35030630
4. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. Dagher T*, **Maslah N***, Edmond V, Cassinat B, Vainchenker W, Giraudier S, Pasquier F, Verger E, Niwa-Kawakita M, Lallemand-Breitenbach V, Plo I, Kiladjian JJ, Villeval JL, de Thé H. *J Exp Med.* 2021 Feb 1;218(2):e20201268. doi:10.1084/jem.20201268. PMID: 33075130 (*co-first authors)
5. Synergistic effects of PRIMA-1^{Met} (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. **Maslah N**, Salomao N, Drevon L, Verger E, Partouche N, Ly P, Aubin P, Naoui N, Schlageter MH, Bally C, Miekoutima E, Rahmé R, Lehmann-Che J, Ades L, Fenaux P, Cassinat B, Giraudier S. *Haematologica.* 2020 Jun;105(6):1539-1551. doi: 10.3324/haematol.2019.218453. Epub 2019 Sep 5. PMID: 31488557

PATENTS

21 305 499.2 (04/15/2021): «IN VITRO TESTS ALLOWING TO IDENTIFY THE POTENTIAL FOR MDM2 INHIBITORS TO INDUCE THE SELECTION OF MUTATIONS IN PATIENTS SUFFERING FROM A MYELOPROLIFERATIVE NEOPLASM»